Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms | Macfadden et al. BMC Psychiatry 2011 11 171 http 1471-244X 11 171 BMC Psychiatry RESEARCH ARTICLE Open Access Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms A -X X zx A l-x f-x 4 4 zxz-X 1 r -X I zx A A A 4 I zx z2 I l-x z I X I Z ZX I I I z Izzx -z3 I zx l-x zx I I_I -X r lz IZ X r 3 l I zx z z I r I I IKXX X z4 -X zx 4 I -X z zx Ỉ Al zx 1 X r 4 Wayne Macfadden Caleb M Adler Ibrahim lurkoz John I Haskins iNOriis Turner and Larry Alphs Abstract Background The objective of this exploratory analysis was to characterize efficacy and onset of action of a 3month treatment period with risperidone long-acting injection RLAI adjunctive to an individual s treatment regimen in subjects with symptomatic Dipolar disorder who relapsed frequently and had significant symptoms of mania and or depression. Methods Subjects with Dipolar disorder with 4 mood episodes in the past 12 months entered the open-label stabilization phase preceding a placebo-controlled double-blind study. Subjects with significant depressive or manic mixed symptoms at baseline were analyzed. Significant depressive symptoms were defined as Montgomery-Asberg Depression Rating Scale MADRS 16 and Young Mania Rating Scale YMRS 16 manic mixed symptoms were YMRS 16 with any MADRS score. Subjects received open-label RLAI 25-50 mg every 2 weeks for 16 weeks adjunctive to a subject s individualized treatment for bipolar disorder mood stabilizers antidepressants and or anxiolytics . Clinical status was evaluated with the Clinical Global Impressions of Bipolar Disorder-Severity CGI-BP-S scale and changes on the MADRS and YMRS scales. Within-group changes were evaluated using paired t tests categorical differences were assessed using Fisher exact test. No adjustment was made for multiplicity. Results 162 subjects who relapsed frequently met criteria for significant mood symptoms at open-label baseline 59 162 had .
